You have no items in your shopping cart.
Oncology & ADC Target Hub
SLC34A2 (NaPi-2b) Research Tools
Explore the critical role of SLC34A2 (NaPi-2b) in phosphate homeostasis and its frequent upregulation in specific subsets of tumor tissues. Validate expression and accelerate targeted therapeutic development with specialized reagents like the Human SLC34A2 ELISA Kit orb756699.
1. What is SLC34A2 (NaPi-2b)?
SLC34A2 (Sodium-dependent phosphate transport protein 2B, also widely known as NaPi-2b) is a multi-pass membrane transporter critical for cellular phosphate homeostasis. While it is physiologically expressed at moderate levels in healthy lung and intestinal tissues, its elevated expression in certain malignancies has positioned it as a compelling clinical target.
Because of its robust cell-surface expression and rapid internalization profile in specific neoplastic subsets, SLC34A2 is considered an active target for Antibody-Drug Conjugates (ADCs). Understanding the expression profile, binding kinetics, and cellular trafficking of this target is essential for rigorous oncology drug development and preclinical screening.
Therapeutic Potential: The efficient internalization of SLC34A2 following specific antibody binding facilitates the intracellular trafficking of antibody-drug conjugates (ADCs) through endosomal and lysosomal pathways, enabling processing and release of cytotoxic payloads within tumor cells. This internalization and trafficking profile makes SLC34A2 an actively investigated target for ADC development.
2. Featured Product: Human SLC34A2 ELISA Kit
Accurate quantification of target expression is the foundation of robust oncology profiling. Our SLC34A2 ELISA assays provide unparalleled sensitivity and reliability for detecting NaPi-2b across diverse sample types.
Standard curve data for the Human SLC34A2 ELISA Kit (orb756699) .
High-Sensitivity Assay
View orb756699 Specifications
Human SLC34A2 ELISA Kit — orb756699
A ready-to-use Sandwich ELISA kit designed for the precise quantitative measurement of Human NaPi-2b in biological samples. Featuring high sensitivity and broad sample compatibility, it is ideal for rigorous biomarker validation and expression profiling.
Product:
Human SLC34A2 ELISA Kit
SKU:
orb756699
Sensitivity:
18.75 pg/ml
Detection Range:
31.25 - 2000 pg/ml
Sample Types:
Serum, Plasma, Cell Lysate
Assay Time:
4 hours
3. Core Target Reagents
Beyond ELISA quantification, visualizing cellular localization and conducting binding assays requires highly specific primary antibodies and purified extracellular domain (ECD) proteins.
Primary Antibodies & Recombinant Proteins
| SKU | Product & Application |
|---|---|
| orb195991 |
SLC34A2 Rabbit Polyclonal Antibody
A meticulously validated, unconjugated polyclonal antibody targeting the human SLC34A2 protein. Suitable for multi-application workflows including ELISA, ICC, IF, IHC-P, and Western Blot. |
| orb2555949 |
SLC34A2 Rabbit Polyclonal Antibody (BF594)
A pre-conjugated formulation (BF594) of our anti-SLC34A2 antibody, specifically optimized for direct Immunocytochemistry (ICC) workflows to visualize membrane localization. |
| orb419212 |
Human SLC34A2 Protein (Fragment 574-689aa)
A highly purified (>85% via SDS-PAGE) recombinant peptide fragment of the human SLC34A2 target, crucial for antibody validation, competitive binding assays, and serving as a quantitative standard. |
| orb1377663 |
SLC34A2 Human Over-expression Lysate
A HEK293T cell transient overexpression lysate (C-Myc/DDK tagged). Functions as an essential positive control for validating antibody specificity in Western Blot applications. |
4. Custom Membrane Protein & ECD Expression Services
As a complex multi-pass trans-membrane transporter, full-length SLC34A2 is notoriously difficult to express, solubilize, and purify without losing its native conformational epitopes. Standard expression systems often yield misfolded aggregates that fail to bind conformational antibodies and experimental ADCs in preclinical screening.
To overcome this, Biorbyt offers specialized Full-Length Membrane & ECD Expression Services. Utilizing advanced proprietary platforms—including Nanodisc technology, Virus-Like Particles (VLPs), and optimized mammalian (HEK293/CHO) or baculovirus/insect cell systems—we deliver highly pure, structurally intact membrane proteins tailored specifically for your biopanning, surface plasmon resonance (SPR), or immunization campaigns.
Explore Membrane Protein Services5. Research-Grade ADC Biosimilars
Benchmarking novel therapeutics requires reliable comparative tools. Our research-grade biosimilars mirror well-documented experimental therapies targeting NaPi-2b, providing essential positive controls for binding dynamics and internalization studies in the laboratory.
Lifastuzumab Biosimilar (Research Grade)
A research-grade monoclonal antibody mirroring the structure of Lifastuzumab, which binds the NaPi-2b target. Perfect as a positive control in comparative preclinical oncology research, target-binding assays, and flow cytometry.
Upifitamab Biosimilar (Research Grade)
Expand your targeted therapy pipeline research with our research-grade Upifitamab biosimilar. An essential tool for benchmarking novel anti-SLC34A2 drug conjugates and evaluating target affinity in vitro.
6. Complete Your Oncology Workflow
Studying a target like SLC34A2 requires profiling the broader cellular environment and tracking downstream efficacy. Explore complementary reagents designed to integrate seamlessly into your oncology research pipeline.
Tumor Profiling
CA-125 (MUC16) Antibodies
Phenotyping distinct cell lines or patient-derived xenografts? Pair your SLC34A2 research with our highly cited primary antibodies targeting classic diagnostic markers like CA-125.
Tumor Profiling
TTF-1 Antibodies
Confirm cellular lineage in tissue arrays alongside NaPi-2b expression using our validated antibodies for TTF-1, a standard marker for specific pulmonary carcinomas.
Pharmacokinetics
ADC Payload Antibodies (Anti-MMAE)
Track the internalization and release of toxic payloads in vitro. We offer specialized antibodies against common ADC chemotherapeutic payloads, including MMAE and MMAF, for precise tracking.
Efficacy Screening
Apoptosis & Cytotoxicity Kits
Testing an experimental anti-SLC34A2 conjugate? Measure therapeutic efficacy and cancer cell death accurately with our Annexin V Apoptosis kits and Caspase-3/7 activity assays.
7. Experimental Design Considerations
Target Specificity
Ensure the specificity of your ADC binding assays and flow cytometry data. Utilize our comprehensive range of IgG1, IgG2, and IgG4 isotype controls vital for validating primary antibody binding mechanisms.
Expression Controls
Establish reliable positive and negative controls for your Western Blots and ELISAs with ready-to-use tumor cell line lysates to benchmark basal expression levels across different cellular phenotypes.
Receptor Internalization
When tracking ADC efficacy in live cells, ensure your secondary detection methods or fluorescent tags are stable in the acidic environment of the lysosome to accurately measure target internalization and payload release.
8. Why Choose Biorbyt for Preclinical Research?
Rigorous Quality Control
All Biorbyt ELISA kits and antibodies undergo stringent validation procedures to ensure high sensitivity, broad dynamic ranges, and batch-to-batch consistency for critical biomarker research.
Workflow Integration
From initial target discovery (proteins and antibodies) to downstream efficacy testing (cytotoxicity and apoptosis assays), we supply the comprehensive toolkit required for rigorous preclinical analysis.
Global Logistics
With a robust global distribution network, we ensure your temperature-sensitive reagents arrive intact and on time, keeping your time-sensitive laboratory research on schedule.
Expert Scientific Support
Backed by a dedicated team of Ph.D. scientists, we provide expert troubleshooting, protocol optimization, and guidance on selecting the right reagents for your specific assay conditions.
9. Frequently Asked Questions
Why is SLC34A2 being investigated as an ADC target?
SLC34A2 (NaPi-2b) is frequently elevated on the surface of specific tumor cells but has limited expression in healthy, essential tissues. Furthermore, it internalizes rapidly upon antibody binding, an essential characteristic that allows the efficient intracellular delivery of experimental cytotoxic payloads in vitro.
Which sample types are compatible with the orb756699 ELISA kit?
The Human SLC34A2 ELISA Kit is validated for use with human serum, plasma, cell culture supernatants, and tissue or cell lysates, making it highly versatile for comprehensive expression profiling workflows.
Are Biorbyt biosimilars suitable for human clinical use?
No. All Biorbyt biosimilars, including our Lifastuzumab and Upifitamab analogs, are strictly for research use only (RUO). They are designed exclusively for preclinical in vitro assays, benchmarking, and laboratory research, and are not intended for diagnostic or therapeutic procedures in humans.
10. Scientific References
The biological mechanisms and therapeutic targeting of SLC34A2 discussed in this guide are supported by the following foundational academic research:
Bodyak, N. D., Mosher, R., Yurkovetskiy, A. V., et al. (2021). The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b. Molecular Cancer Therapeutics, 20(5), 896-905. https://doi.org/10.1158/1535-7163.mct-20-0183
Banerjee, S., Oza, A. M., Birrer, M. J., et al. (2018). Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Annals of Oncology, 29(4), 917-923. https://doi.org/10.1093/annonc/mdy023
Gerber, D. E., Infante, J. R., Gordon, M. S., et al. (2020). Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clinical Cancer Research, 26(2), 364-372. https://doi.org/10.1158/1078-0432.ccr-18-3965